XPhyto Therapeutics innovate and commercialize next-generation pharmaceutical and diagnostic investment opportunities. The XPhyto Laboratories arm of the company specializes in the application of psychedelic compounds as impactful solutions to mental health disorders. The company is aiming to produce psychedelic compounds on an industrial scale.
XPhyto will develop psychedelic medicine to treat mental health-related medical conditions such as depression, anxiety, addiction, and trauma-related stress disorder. Currently, XPhyto are working on developing psilocybin and mescaline.
XPhyto Therapeutics
“Our research and development in psychedelic treatments with modern scientific methods and validation has the potential to change the narrative on mental health-related medical conditions.”
News
- XPhyto Therapeutics says it is rapidly advancing its mescaline program for psychedelic therapies (Proactive Investors, June 2021)
Activities
B2B
B2C
Pharmaceutical
Biotech
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates